The new microneedle system improves hair growth in alopecia treatment.
20 citations
,
February 2017 in “European journal of pharmaceutical sciences” The MPA-ISO cocrystal improved solubility and dissolution rate, while the others did not.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
A new topical treatment using micelles shows promise for safer and more effective hair regrowth in androgenetic alopecia.
1 citations
,
May 2011 in “Hair transplant forum international” Injectable ACell with blood serum/PRP may slow hair loss and regrow thinning hair.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
33 citations
,
November 2020 in “AAPS PharmSciTech”
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
January 2026 in “Journal of Materials Chemistry B” TA-Ado effectively promotes hair growth and reduces hair loss.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
23 citations
,
March 1994 in “Fertility and sterility” Most patients improved with oral contraceptives, but some needed additional treatment.
20 citations
,
September 2005 in “Endocrinology” Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.
January 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Metformin may improve acanthosis nigricans by reducing insulin resistance.
3 citations
,
November 2018 in “Journal of cellular physiology” Serenoa repens and N-acetyl glucosamine/milk proteins complex may help with hair growth and prevent hair loss.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
30 citations
,
July 2009 in “Experimental and clinical endocrinology & diabetes” Cyproterone acetate effectively treats sexual disorders by reducing sexual functions and is generally well-tolerated.
2 citations
,
January 2021 in “PLANT ARCHIVES” Andrographolide-loaded topical nanocarriers are a safe and effective treatment for psoriasis.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
January 2023 in “Figshare” Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
Cepharanthine could be a strong antiviral against COVID-19.